Clinical trials
Phase 2 clinical trials
Below are recruiting phase 2 clinical trials, each written for real people, not researchers. We’re tracking 295 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03815279Enrolling by invitationPhase 2
Trial for active or high-risk smoldering myeloma treatments
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
ReykjavikAges 18 years+ - NCT02621021RecruitingPhase 2
Immune cell therapy for advanced melanoma
This trial tests a treatment that uses your own immune cells, called tumor-infiltrating lymphocytes (TILs), to fight melanoma. Some participants also get a drug called pembrolizumab. The goal is to see if this approach can shrink tumors.
Bethesda, MarylandAges 18–72 - NCT01297400RecruitingPhase 2
Testing a topical treatment for thermal burns
This trial studies whether a topical medicine (MW-III) is safe and helps heal thermal burns. It is for adults with relatively limited burn size and certain burn depths, while excluding infected or high-risk wounds.
Phoenix, ArizonaAges 18 years+ - NCT07563738RecruitingPhase 1/Phase 2
ODM-212 with cancer immunotherapy for advanced solid tumors
This trial tests a new drug called ODM-212 combined with existing cancer treatments for mesothelioma, pancreatic cancer, or lung cancer with a specific genetic mutation. The study aims to find the right dose and see if adding ODM-212 helps these treatments work better.
Irving, TexasAges 18 years+ - NCT07636785RecruitingPhase 1/Phase 2
VMD-102 Drug Study for Advanced Cancers
This study tests a new drug called VMD-102 in patients with advanced liver cancer, melanoma, kidney cancer, lung cancer, or colon cancer that hasn't responded to standard treatments. The trial will help determine if VMD-102 is safe and effective at slowing or stopping cancer growth.
Scottsdale, ArizonaAges 18–75 - NCT04679584Recruiting
Study of long-term effects after COVID-19 infection
This study looks at how COVID-19 can affect health and quality of life over the long term. It may help researchers understand symptoms that can last and what changes people experience after recovery.
Würzburg, BavariaAges 18 years+ - NCT07580586RecruitingPhase 1
Study of BV100's effect on polymyxin B in healthy volunteers
This early-stage study tests how a new drug called BV100 affects how your body processes polymyxin B, an antibiotic. Researchers want to understand how these two drugs interact so they can develop safer treatments.
ViennaAges 18–55 - NCT06971094RecruitingPhase 3
Gene therapy for type 2 spinal muscular atrophy
This trial tests a new gene therapy called GC101 given as a one-time injection into the spinal fluid for people with type 2 spinal muscular atrophy (SMA). It may help improve motor function.
BeijingAges 2–12 - NCT06835725RecruitingPhase 2
Comparing two prostate radiation schedules for intermediate risk
This trial compares giving radiation in 2 treatments versus 5 treatments for prostate cancer that hasn't spread. It's for men with low or intermediate risk prostate cancer who are healthy enough to undergo a short course of targeted radiation.
Surrey, British ColumbiaAges 18 years+ - NCT06126588RecruitingPhase 2
Everolimus and Lutathera for refractory meningioma
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
Vandœuvre-lès-Nancy, Grand EstAges 18–80 - NCT05508464Recruiting
Test targeted radiation to control many metastases safely
This study tests whether a focused, high-precision type of radiation can control many cancer spread-out spots (“metastases”) at the same time, while keeping side effects acceptable. It may help people with many metastases live longer or have better disease control by aiming treatment at every treatable spot.
London, OntarioAges 18 years+ - NCT07525375RecruitingPhase 2
Lung Function Study of Inhaled Glycopyrronium With BFF in Children With Asthma
This study tests whether adding a medication called glycopyrronium to a common asthma inhaler (BFF) helps children ages 4–12 breathe better. Researchers will measure lung function and compare two different doses of the added medication.
Bakersfield, CaliforniaAges 4–11 - NCT07653477RecruitingPhase 3
New diabetes drug for type 2 diabetes not well controlled with metformin
This trial tests an investigational drug called UBT251 for people with type 2 diabetes whose blood sugar is not well controlled despite taking metformin, either alone or with another diabetes medicine. The goal is to see if it can lower blood sugar levels more than a placebo.
ShanghaiAges 18–75 - NCT07659574RecruitingPhase 3
Study of UBT251 injection for type 2 diabetes not controlled by diet and exercise
This trial tests a new injected drug (UBT251) for people with type 2 diabetes who haven't been able to control their blood sugar with diet and exercise alone. It aims to see if the drug can help lower blood sugar levels safely.
Changsha, HunanAges 18–75 - NCT06694935RecruitingPhase 1
Testing QX1206 in type 2 diabetes with fatty liver
This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.
TorontoAges 18–64 - NCT07488546Enrolling by invitationPhase 1/Phase 2
HCL001 cell therapy for advanced liver cirrhosis
This trial tests a new cell injection called HCL001 for people with decompensated cirrhosis (advanced liver scarring causing complications). The goal is to see if it's safe and helps improve liver function. It may be an option if you've tried standard treatments and meet specific health criteria.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07072234RecruitingPhase 1
CAR NK cell therapy for advanced clear cell kidney cancer
This trial tests a new type of immune cell therapy (CAR NK cells) that targets a protein called CD70 on kidney cancer cells. It's for people with advanced clear cell kidney cancer that hasn't responded to standard treatments.
Houston, TexasAges 18 years+ - NCT06077838Recruiting
RELAXaHEAD app test for migraine relief
This study tests a smartphone app called RELAXaHEAD that teaches relaxation techniques to help people with migraine. If you have 4–29 headache days per month and haven't tried relaxation therapy for headaches recently, this app might help reduce your symptoms.
New York, New YorkAges 16–80 - NCT07568678RecruitingPhase 1
Testing HMS1005 in adults with type 2 diabetes
This study tests a new medicine called HMS1005 in people with type 2 diabetes. Researchers want to see how safe it is and how the body responds to different doses. You may qualify if you have type 2 diabetes that is either untreated or controlled with common diabetes medications.
Miami, FloridaAges 18–65 - NCT06830239RecruitingPhase 2
Neoadjuvant dostarlimab for resectable stage III colon cancer
This trial tests an investigational immunotherapy drug called dostarlimab given before surgery for colon cancer. It is for people whose tumor is MMR-proficient (also called MSS) and is large enough or has spread to nearby lymph nodes but not to other parts of the body. The goal is to see if this treatment can shrink the tumor before surgery.
LeuvenAges 18 years+ - NCT07652242RecruitingPhase 1
A RNA vaccine for stage 2-3 triple negative breast cancer
This trial tests an experimental RNA vaccine (ITI-5000) designed to help your immune system fight triple-negative breast cancer. It is for people with stage 2 or 3 disease who have already had some cancer treatment.
Grand Rapids, MichiganAges 18 years+ - NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT07167693RecruitingPhase 1/Phase 2
Testing arginine for diabetic ketoacidosis in type 2 diabetes
This trial tests if an IV medicine called arginine hydrochloride can help manage diabetic ketoacidosis (DKA) in people with type 2 diabetes. It's for those who come to the ER with very high blood sugar and ketones.
Detroit, MichiganAges 18 years+ - NCT06614101Recruiting
Breath test for monitoring blood sugar
This study is testing a new device that measures blood sugar levels by analyzing your breath. It is for people with type 2 diabetes or those who are overweight, to see if the breath test can work as a non-invasive way to monitor glucose.
Salies-du-Salat, FranceAges 18 years+
Hear when a new Phase 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for phase 2?
- Yes. Clin2 currently lists 295 recruiting phase 2 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a phase 2 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a phase 2 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.